About OTX-TIC (travoprost implant) for Intracameral Use OTX-TIC is a bioresorbable intracameral implant containing micronized travoprost that is injected into the anterior chamber of the eye and is ...
Learn more about whether Ocular Therapeutix, Inc. or Phibro Animal Health Corporation is a better investment based on AAII's ...
Ocular Therapeutix to receive $12 million upfront fee and development and commercialization milestones and other payments of up to $91 million plus additional royalties on future product sales BEDFORD ...
Analysts' ratings for Ocular Therapeutix (NASDAQ:OCUL) over the last quarter vary from bullish to bearish, as provided by 7 analysts. The table below provides a snapshot of their recent ratings, ...
BEDFORD, Mass., April 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (OCUL) (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and ...
In the latest quarter, 4 analysts provided ratings for Ocular Therapeutix (NASDAQ:OCUL), showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below ...
Ocular Therapeutix, Inc. (NASDAQ: OCUL, 'Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will participate in several ...
Dextenza ® Net Product Revenue in the Fourth Quarter of 2022 is Estimated to be $13.6 million, Growing Approximately 14% Over Previous Quarter and Approximately 11% Over Same Quarter of Prior Year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results